Dukoral Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Dukoral market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to higher government investments in vaccination programs and public health initiatives, increased awareness of cholera prevention among travelers and local populations, rising demand for oral cholera vaccines, the growing prevalence of antibiotic-resistant infections, heightened awareness of waterborne diseases, and a rise in the incidence of cholera and diarrhea outbreaks.

Growth during the market's forecast period can be attributed to expanding government initiatives to enhance vaccination programs, a growing focus on preventive healthcare, increasing awareness of the importance of cholera vaccination, and rising demand for oral vaccines. Key trends expected in this period include advancements in oral vaccine formulations, improvements in stability and shelf life to enable better distribution in regions with limited healthcare infrastructure, the development of enhanced vaccine formulations, technological innovations, and new manufacturing techniques.

The increasing number of cholera cases is expected to drive the growth of the Dukoral market. Cholera is an acute diarrheal disease caused by ingesting food or water contaminated with Vibrio cholerae, which can lead to severe dehydration and, in extreme cases, death. Factors such as poor sanitation, contaminated water, and climate change are contributing to the rise of cholera, creating conditions conducive to outbreaks. Dukoral, an oral cholera vaccine, helps reduce the risk of infection by stimulating immunity against the Vibrio cholerae bacteria and its toxin. For example, in September 2024, the World Health Organization (WHO) reported a 13% increase in cholera cases in 2023, along with a 71% rise in fatalities compared to 2022, resulting in over 4,000 deaths from a preventable and treatable disease. Consequently, the increasing incidence of cholera cases is expected to drive the growth of the Dukoral market.

A key trend in the Dukoral market is the development of more affordable oral cholera vaccines, which aim to enhance vaccine efficacy and simplify administration. These low-cost vaccines are designed to prevent cholera and provide easier access to vaccination, especially in resource-limited areas. For instance, in April 2023, the International Vaccine Institute (IVI), based in South Korea, partnered with the University of Gothenburg in Sweden to develop DuoChol, a low-cost oral cholera vaccine. This collaboration focuses on advancing the development of DuoChol, which features a dry formulation of inactivated bacterial whole cells and cholera toxin B subunit in capsule form. DuoChol offers similar components to Dukoral but is more stable at higher temperatures and has reduced weight and volume. A Phase I clinical trial will be conducted in Sweden, funded by the Wellcome Trust and the Swedish government.

In July 2023, NorthX Biologics, a biotechnology company based in Sweden, acquired a manufacturing unit from Valneva SE for an undisclosed amount. This acquisition aims to enhance NorthX Biologics’ capacity to produce advanced biologics and support the development of innovative therapies, helping the company strengthen its position in the Nordic biopharmaceutical market. Valneva SE, a France-based biotechnology company, is known for developing and commercializing vaccines, including Dukoral, an oral cholera vaccine.

The key player in the dukoral market is Valneva SE.

Asia-Pacific was the largest region in the dukoral market in 2024. The regions covered in dukoral report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dukoral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dukoral is an oral vaccine designed to protect against cholera and certain types of diarrhea caused by enterotoxigenic Escherichia coli (ETEC) bacteria. It contains an inactivated cholera toxin and a recombinant cholera toxin B subunit, which work together to stimulate the body's immune response. This vaccine is typically recommended for travelers visiting regions with a high risk of cholera or ETEC infection.

The primary indications for Dukoral include cholera and traveler's diarrhea. Cholera is a severe bacterial infection caused by *Vibrio cholerae*, typically spread through contaminated water or food, and leads to acute diarrhea and dehydration. Dukoral provides protection by prompting the immune system to combat the bacteria before infection occurs. The vaccine is distributed through pharmacies, travel clinics, and healthcare providers, with end users including hospitals, clinics, ambulatory care, and home care settings.

The dukoral market research report is one of a series of new reports that provides dukoral market statistics, including dukoral industry global market size, regional shares, competitors with a dukoral market share, detailed dukoral market segments, market trends and opportunities, and any further data you may need to thrive in the dukoral industry. This dukoral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dukoral market consists of sales of vaccine kits, oral liquid formulations, and oral capsule formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.